Retrospective Study to evaluate response to TNFi in PsA in UK practice
Research type
Research Study
Full title
A multicentre retrospective study to evaluate the response to Tumour Necrosis Factor Alpha inhibitor treatment of psoriatic arthritis in UK clinical practice
IRAS ID
171467
Contact name
Neil McHugh
Contact email
Sponsor organisation
NOVARTIS Pharmaceuticals UK Limited
Duration of Study in the UK
0 years, 10 months, 1 days
Research summary
The aim of this study is to describe the response to treatment using the Psoriatic Arthritis Response Criteria (PsARC) in patients with Psoriatic Arthritis (PsA) who are receiving biologic therapies, called Tumour Necrosis Factor Alpha inhibitors(TNFis), during normal clinical care in the UK NHS. The results of this study will contribute to the evidence base on the use of second and subsequent biologics in patients with psoriatic arthritis (PsA)which will be useful in the future to clinicians and patients when making decisions about treatment options following a first biologic.
The study will be a retrospective observational multicentre descriptive study involving review of medical records. It will be conducted at up to 15 NHS Hospital Rheumatology clinics, collecting data from 150 patients, approximately 10 patients from each centre.
REC name
East of England - Cambridgeshire and Hertfordshire Research Ethics Committee
REC reference
15/EE/0029
Date of REC Opinion
19 Jan 2015
REC opinion
Favourable Opinion